Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 563Neoplasms 462Carcinoma, Non-Small-Cell Lung 422Prostatic Neoplasms 344Colorectal Neoplasms 325Lung Neoplasms 269Multiple Myeloma 235Neoplasm Metastasis 197Pancreatic Neoplasms 189Leukemia, Myeloid, Acute 187Ovarian Neoplasms 182Melanoma 153Squamous Cell Carcinoma of Head and Neck 143Head and Neck Neoplasms 121Recurrence 119Carcinoma, Renal Cell 119Carcinoma, Hepatocellular 119Stomach Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Glioblastoma 114Endometrial Neoplasms 114Lymphoma 113Brain Neoplasms 111Lymphoma, Non-Hodgkin 108Uterine Cervical Neoplasms 101Triple Negative Breast Neoplasms 99Hematologic Neoplasms 98Urinary Bladder Neoplasms 97Glioma 91Leukemia, Lymphocytic, Chronic, B-Cell 88

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × 30 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡